Patents by Inventor Szu-Wen Wang

Szu-Wen Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200054574
    Abstract: For applications in drug delivery, “smart” materials have been designed to respond to conditions within microenvironments of tissues or cells. The present invention features stimuli-responsive cross-linked hydrogels that respond to specific metabolites of disease. For example, protein-polymer materials of the present invention are configured to release their drug cargo upon encountering the higher lactate concentrations within tumor microenvironments.
    Type: Application
    Filed: July 23, 2019
    Publication date: February 20, 2020
    Inventors: Szu-Wen Wang, Tae Il Kim, Kenneth J. Shea, Krista Fruehauf, Edward L. Nelson
  • Publication number: 20190101669
    Abstract: The technology relates to a prophylactic bandage contact lens that prevents microbial infections in an eye as well as treats infection by dispensing antimicrobial medication at controlled rates. In one embodiment, the invention provides a bandage with nanostructures, and provides a continuous treatment over 10 days and shields the eye from the environment, significantly diminishing the risk of infection while allowing damaged tissues to heal.
    Type: Application
    Filed: October 3, 2018
    Publication date: April 4, 2019
    Applicant: Regents of The University of California
    Inventors: Albert Yee, Rachel Rosenzweig, Mary Nora Dickson, Elena Liang, Szu-Wen Wang
  • Publication number: 20090291474
    Abstract: Provided herein are isolated polynucleotides encoding collagen-like polypeptide domains and the encoded polypeptides. In one such polypeptide, at least a portion of the encoded collagen-like polypeptide domain is in the form of Gly-X-Y triads, where X and Y symbolize individual amino acids; X is proline in at least 20% of the triads; Y is proline in at least 20% of the triads. The encoding polynucleotide of such a polypeptide encodes a region having at least 50 consecutive amino acids, wherein the region is at least 90% identical to an amino acid sequence of a naturally occurring collagen polypeptide; and no more than 98% of the nucleotides of the collagen-like polypeptide domain-encoding portion of the polynucleotide fall into a window of 100 consecutive nucleotides in which the nucleotides of the window have greater than 98% identity to a naturally occurring collagen-encoding nucleotide sequence.
    Type: Application
    Filed: May 15, 2009
    Publication date: November 26, 2009
    Inventors: Szu-Wen Wang, Nancy A. Da Silva, She-Pin Hung, Richard H. Lathrop
  • Publication number: 20060148877
    Abstract: Liquid formulations of celecoxib have been found to provide faster pain relief than conventional solid formulations of celecoxib. The present invention provides combinations of excipients in which celecoxib is highly soluble for formulation as pharmaceutical compositions.
    Type: Application
    Filed: November 25, 2003
    Publication date: July 6, 2006
    Applicant: TransForm Pharmaceuticals, Inc.
    Inventors: Steven Bernstein, Hongming Chen, Colin Gardner, Meegan LeMott, Szu-Wen Wang
  • Publication number: 20040092428
    Abstract: The invention concerns excipients or combinations thereof suitable for preparing an oral formulation containing a pharmaceutical agent. More particularly, the invention is directed to stable, efficacious and bioavailable oral pharmaceutical formulations comprising paclitaxel, derivatives of paclitaxel and pharmaceutically acceptable salts thereof. The formulations of the invention increase bioavailability of paclitaxel when dissolved in the gastrointestinal system. The formulations of the invention are useful for administering paclitaxel, its derivatives, or pharmaceutically acceptable salts of such derivatives to patients in need thereof. The formulations of the invention are particularly suitable for oral administration to mammals including humans.
    Type: Application
    Filed: February 5, 2003
    Publication date: May 13, 2004
    Inventors: Hongming Chen, Zhong Zhang, Szu-Wen Wang